DESVENLAFAXINE DIN 02543672
Health Canada record
| Active ingredient(s) | DESVENLAFAXINE 50 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AX23 DESVENLAFAXINE |
| Original market date | 12-Apr-2024 |
| Current status date | 12-Apr-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DESVENLAFAXINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02466996 | APO-DESVENLAFAXINE | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02466988 | APO-DESVENLAFAXINE | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02535114 | DESVENLAFAXINE | SANIS HEALTH INC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02554976 | DESVENLAFAXINE | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02535106 | DESVENLAFAXINE | SANIS HEALTH INC | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02543680 | DESVENLAFAXINE | PRO DOC LIMITEE | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02554968 | DESVENLAFAXINE | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02538423 | SANDOZ DESVENLAFAXINE | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02538415 | SANDOZ DESVENLAFAXINE | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32292 | 2023-12-05 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement Between Two Manufacturers |
International API supply for DESVENLAFAXINE
26 active FDA Drug Master Files.
Request a quote for DESVENLAFAXINE